Presents a brief overview of the eight COVID-19 editorials published in DMPHP over the past year and using them as a framework to follow the evolution of the Pandemic over time. A review of the salient epidemiological and clinical dimensions of COVID-19 over time is given as well as a discussion of the medical and public health impacts of the disease and the interventions and policies put in place to contain and mediate the virus.
A new study conducted at the Galveston National Laboratory at the The University of Texas Medical Branch at Galveston (UTMB) has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus. The study was published today in Nature Communications.
Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses. Will the same apply to COVID-19 vaccines? Researchers from Charité - Universitätsmedizin Berlin compared the evolution of endemic 'common cold' coronaviruses with that of influenza viruses. The researchers predict that, while the pandemic is ongoing, vaccines will need to undergo regular updates. A few years into the post-pandemic period, however, vaccines are likely to remain effective for longer.
Researchers led by the University of Missouri create a new method for analyzing large amounts of biological data to help scientists draw faster conclusions for possible treatments.
A team led by Markus Hoffmann and Stefan Pöhlmann of the German Primate Center - Leibniz Institute for Primate Research and Jan Münch of the Ulm University Medical Centre has found that the SARS-CoV-2 variants B.1.351 and P.1 are no longer inhibited by an antibody used for COVID-19 therapy. In addition, these variants are less efficiently inhibited by antibodies from recovered patients and vaccinated individuals.
Scientists have shown that SARS-CoV-2, the virus that causes COVID-19, can infect specific cells in the salivary gland in the mouth. The study revealed that salivary gland cells could play a role in transmission of the SARS-CoV-2 virus to the lungs or digestive system via saliva, and could help explain some of the oral symptoms experienced by COVID-19 patients. Understanding the involvement of mouth cells could inform strategies to reduce viral transmission.
An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth. The findings point to the possibility that the mouth plays a role in transmitting SARS-CoV-2 to the lungs or digestive system via saliva laden with virus from infected oral cells. A better understanding of the mouth's involvement could inform strategies to reduce viral transmission within and outside the body.
ITQB NOVA researchers characterize a possible therapeutic target to fight Covid-19. The study now published on FEBSJournal gives crucial clues to weaken the SARS-CoV-2
A research group at RIKEN, Japan has found that glycans play an important role in the structural changes that take place when the virus which causes COVID-19 invades human cells. Their discovery based on supercomputer-based simulations could contribute to the molecular design of drugs for the prevention and treatment of COVID-19.
Experimental flu shots have now been developed that protect animals from a wide variety of season and pandemic influenza strains. The vaccine candidate is being advanced toward clinical testing. If proven safe and effective, these next-generation influenza vaccines could replace seasonal options by protecting against more strains that current vaccines don't adequately cover.